• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury

Posted on: Monday, 4 May 2009, 09:30 CDT

SAN DIEGO, May 4 /PRNewswire-FirstCall/ -- Bio-Matrix Scientific Group Inc. (OTC Bulletin Board: BMSN)(http://www.BMSN.us) and Entest BioMedical Inc., its wholly owned subsidiary, announced today they have jointly submitted a Project Summary Report to the U.S. Army Medical Research and Materiel Command (USAMRMC) for consideration of funding to study the therapeutic potential of adipose-derived stem cells (ASCs) harvested from liposuction for treating Traumatic Brain Injury (TBI). The USAMRMC provides solutions to medical problems of importance to the American warfighter at home and abroad. BMSN is a San Diego-based biotechnology research and development company. Entest BioMedical Inc. is focused on research & development in regenerative medicine.

Currently, there are no effective therapeutic approaches to reverse the injury. Combat-related brain injuries in service members returning from the ongoing conflicts in Iraq and Afghanistan appear to be higher than in previous conflicts. Walter Reed Army Medical Center has stated that nearly 30% of all patients with combat-related injuries have sustained a TBI mostly from roadside bombs and other explosives.

The BMSN-Entest BioMedical Project Summary Report for review and funding, entitled "An Adipose-derived Stem Cell Therapy for Traumatic Brain Injury," is authored by Feng Lin, M.D., Ph.D., BMSN's Laboratory/Scientific Director. He has extensive experience with tissue imaging, cell and molecular biology, animal model work, among other expertise areas. Dr. Lin is serving as the Chief Investigator for Entest BioMedical Inc.

"The objective of our proposal is to develop an effective ASC-based therapy for TBI," said David Koos, Chairman and CEO of BMSN. Adipose, or fat, tissue is the most abundant and accessible source of adult stem cells that can be easily harvested from liposuction, and can also differentiate into neural cells, he noted.

"Specifically, we will substantially study the therapeutic effect of ASCs on TBI-associated brain ischemia and inflammation via intravenous administration or by intro-cerebral transplantation. It is plausible that our proposed study will pave the way for an ASC-based therapy for TBI, which hopefully will be much more feasible and safer than other stem cell-based approaches," said Koos.

About Bio-Matrix Scientific Group

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotech research and development company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, asceptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.

About Entest BioMedical Inc.:

Entest BioMedical Inc. is a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. The Company is involved with the development of testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

SOURCE Bio-Matrix Scientific Group, Inc.

Source: PR Newswire

More News in this Category